GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Boundless Bio Inc (NAS:BOLD) » Definitions » Notes Receivable

BOLD (Boundless Bio) Notes Receivable : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Boundless Bio Notes Receivable?

Boundless Bio's Notes Receivable for the quarter that ended in Dec. 2024 was $0.00 Mil.


Boundless Bio Notes Receivable Historical Data

The historical data trend for Boundless Bio's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boundless Bio Notes Receivable Chart

Boundless Bio Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Notes Receivable
- - - -

Boundless Bio Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Boundless Bio Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Boundless Bio Notes Receivable Related Terms

Thank you for viewing the detailed overview of Boundless Bio's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Boundless Bio Business Description

Traded in Other Exchanges
N/A
Address
9880 Campus Point Drive, Suite 120, San Diego, CA, USA, 92121
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.